

EGF Receptor Exon 20 insertions

1. Ahmed ZA, Moatter T, Siddiqui A, Pervez S.: Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy. Asian Pac J Cancer Prev. 2014;15(17):7125-8.
2. Arcila ME, Nafa K, Chaft JE, Rekhtman N, Lau C, Reva BA, Zakowski MF, Kris MG, Ladanyi M.: EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics. Mol Cancer Ther. 2013 Feb;12(2):220-9.
3. Ayoola A, Barochia A, Belani K, Belani CP.: Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update. Cancer Invest. 2012 Jun;30(5):433-46.
4. Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranet J.: Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol. 2014 Jan;25(1):126-31.
5. Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathol. 2013 Sep;121(9):500-7.
6. Cai YR, Dong YJ, Wu HB, Liu ZC, Zhou LJ, Su D, Chen XJ, Zhang L, Zhao YL.: Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas. Sci Rep. 2016 Apr 5;6:23755.
7. Chai X, Ren P, Wei B, Ma J, Mai L, Cram DS, Song Y, Guo Y.: A comparative study of EGFR oncogenic mutations in matching tissue and plasma samples from patients with advanced non-small cell lung carcinoma. Clin Chim Acta. 2016 Jun 1;457:106-11.
8. Chan RT.: Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival. Asia Pac J Clin Oncol. 2018 Mar;14 Suppl 1:7-9.

9. Chen D, Song Z, Cheng G.: Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations. *Onco Targets Ther.* 2016 Jul 8;9:4181-6.
10. Cho J, Chen L, Sangji N, Okabe T, Yonesaka K, Francis JM, Flavin RJ, Johnson W, Kwon J, Yu S, Greulich H, Johnson BE, Eck MJ, Jänne PA, Wong KK, Meyerson M. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. *Clin Cancer Res.* 2011 Mar 1;17(5):1131-9.
11. Estrada-Bernal, A, Doak, AE, Le, AT, Zhu, H, Chen, N, Silva, S, Smaill, JB, Patterson, AV, Doebele, RC. Antitumor activity of tarloxotinib, a hypoxia-activated EGFR TKI, in patient-derived lung cancer cell lines harboring EGFR exon 20 insertions. Abstract A157. TARG-17-A157 Published January 2018.
12. Felip E, Barlesi F, Besse B, Chu Q, Gandhi L, Kim SW, Carcereny E, Sequist LV, Brunsvig P, Chouaid C, Smit EF, Groen HJM, Kim DW, Park K, Avsar E, Szpakowski S, Akimov M, Garon EB. Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer. *J Thorac Oncol.* 2017 Dec 13.
13. Floc'h N, Martin MJ, Riess JW, Orme JP, Staniszewska AD, Menard L, Cuomo ME, O'Neill DJ, Ward RA, Finlay MRV, McKerrecher D, Cheng M, Vang DP, Tsai RA, Keck JG, Gandara DR, Mack PC, Cross DA.: Anti-tumor activity of osimertinib, an irreversible mutant-selective EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions. *Mol Cancer Ther.* 2018 Feb 26. [Epub ahead of print]
14. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M.: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. *PLoS Med.* 2005 Nov;2(11):e313.
15. Harada T, Lopez-Chavez A, Xi L, Raffeld M, Wang Y, Giaccone G.: Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. *Oncogene.* 2011 Apr 14;30(15):1744-52
16. Heigener DF, Schumann C, Sebastian M, Sadjadian P, Stehle I, Märten A, Lüers A, Griesinger F, Scheffler M; Afatinib Compassionate Use Consortium (ACUC).: Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. *Oncologist.* 2015 Oct;20(10):1167-74.

17. Hirano T, Yasuda H, Hamamoto J, Nukaga S, Masuzawa K, Kawada I, Naoki K, Niimi T, Mimasu S, Sakagami H, Soejima K, Betsuyaku T.: Pharmacological and structural characterizations of naquotinib, a novel third generation EGFR tyrosine kinase inhibitor, in EGFR mutated non-small-cell lung cancer. Mol Cancer Ther. 2018 Feb 21. [Epub ahead of print]
18. Hirano T, Yasuda H, Tani T, Hamamoto J, Oashi A, Ishioka K, Arai D, Nukaga S, Miyawaki M, Kawada I, Naoki K, Costa DB, Kobayashi SS, Betsuyaku T, Soejima K.: In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer. Oncotarget. 2015 Nov 17;6(36):38789-803
19. Jain A, Lim C, Gan EM, Ng DZ, Ng QS, Ang MK, Takano A, Chan KS, Tan WM, Kanesvaran R, Toh CK, Loo CM, Hsu AA, Devanand A, Lim CH, Koong HN, Koh T, Fong KW, Yap SP, Kim SW, Chowbay B, Oon L, Lim KH, Lim WT, Tan EH, Tan DS. Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. PLoS One. 2015 May 8;10(5):e0123587.
20. Jia Y, Juarez J, Li J, Manuia M, Niederst MJ, Tompkins C, Timple N, Vaillancourt MT, Pferdekamper AC, Lockerman EL, Li C, Anderson J, Costa C, Liao D, Murphy E, DiDonato M, Bursulaya B, Lelais G, Barretina J, McNeill M, Epple R, Marsilje TH, Pathan N, Engelman JA, Michellys PY, McNamara P, Harris J, Bender S, Kasibhatla S.: EGF816 Exerts Anticancer Effects in Non-Small Cell Lung Cancer by Irreversibly and Selectively Targeting Primary and Acquired Activating Mutations in the EGF Receptor. Cancer Res. 2016 Mar 15;76(6):1591-602.
21. Kang HJ, Hwangbo B, Lee JS, Kim MS, Lee JM, Lee GK.: Comparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung Cancer. PLoS One. 2016 Sep 29;11(9):e0163652.
22. Karachaliou N, Molina-Vila MA, Rosell R.: The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer. Expert Rev Respir Med. 2015 Jun;9(3):241-4.
23. Khan NA, Mirshahidi S, Mirshahidi HR.: A novel insertion mutation on exon 20 of epidermal growth factor receptor, conferring resistance to erlotinib. Case Rep Oncol. 2014 Jul 16;7(2):491-6.

24. Kobayashi Y, Mitsudomi T: Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy. Cancer Sci. 2016 Sep;107(9):1179-86
25. Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.: Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res. 2017 May 15;77(10):2712-2721.
26. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T.: Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res. 2004 Dec 15;64(24):8919-23.
27. Kuiper JL, Hashemi SM, Thunnissen E, Snijders PJ, Grünberg K, Bloemena E, Sie D, Postmus PE, Heideman DA, Smit EF.: Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment. Br J Cancer. 2016 Dec 6;115(12):1504-1512.
28. Lai Y, Zhang Z, Li J, Sun D, Zhou Y, Jiang T, Han Y, Huang L, Zhu Y, Li X, Yan X.: EGFR mutations in surgically resected fresh specimens from 697 consecutive Chinese patients with non-small cell lung cancer and their relationships with clinical features. Int J Mol Sci. 2013 Dec 17;14(12):24549-59.
29. Leduc C, Merlio JP, Besse B, Blons H, Debieuvre D, Bringuier PP, Monnet I, Rouquette I, Fraboulet-Moreau S, Lemoine A, Pouessel D, Mosser J, Vaylet F, Langlais A, Missy P, Morin F, Moro-Sibilot D, Cadranet J, Barlesi F, Beau-Faller M; French Cooperative Thoracic Intergroup (IFCT). Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program. Ann Oncol. 2017 Nov 1;28(11):2715-2724.
30. Lin YT, Liu YN, Wu SG, Yang JC, Shih JY.: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 May;18(3):324-332.e1.
31. Lund-Iversen M, Kleinberg L, Fjellbirkeland L, Helland Å, Brustugun OT.: Clinicopathological characteristics of 11 NSCLC patients with EGFR-exon 20 mutations. J Thorac Oncol. 2012 Sep;7(9):1471-3.

32. Naderi S, Ghorra C, Haddad F, Kourie HR, Rassy M, El Karak F, Ghosn M, Abadjian G, Kattan J.: EGFR mutation status in Middle Eastern patients with non-squamous non-small cell lung carcinoma: A single institution experience. *Cancer Epidemiol.* 2015 Dec;39(6):1099-102.
33. Naidoo J, Sima CS, Rodriguez K, Busby N, Nafa K, Ladanyi M, Riely GJ, Kris MG, Arcila ME, Yu HA.: Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. *Cancer.* 2015 Sep 15;121(18):3212-3220.
34. Ning J, Wu Q, Liu Z, Wang J, Lin X.: Mapping inhibitor response to the in-frame deletions, insertions and duplications of epidermal growth factor receptor (EGFR) in non-small cell lung cancer. *J Recept Signal Transduct Res.* 2016;36(1):37-44.
35. Noronha V, Choughule A, Patil VM, Joshi A, Kumar R, Susan Joy Philip D, Banavali S, Dutt A, Prabhash K.: Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment. *Onco Targets Ther.* 2017 Jun 9;10:2903-2908.
36. O'Kane GM, Bradbury PA, Feld R, Leighl NB, Liu G, Pisters KM, Kamel-Reid S, Tsao MS, Shepherd FA.: Uncommon EGFR mutations in advanced non-small cell lung cancer. *Lung Cancer.* 2017 Jul;109:137-144.
37. Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA.: Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. *J Thorac Oncol.* 2013 Feb;8(2):179-84.
38. Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H, Wang R, Ye T, Luo X, Zhang Y, Li B, Cai D, Shen L, Sun Y, Chen H.: Prevalence, clinicopathologic characteristics, and molecular associations of EGFR exon 20 insertion mutations in East Asian patients with lung adenocarcinoma. *Ann Surg Oncol.* 2014 Dec;21 Suppl 4:S490-6.
39. Poziotinib Shows Promise for Rare Lung Cancer. *Cancer Discov.* 2018 Jan;8(1):OF4-OF4. (no authors listed).
40. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB^{6,7}, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and clinical activity of an EGFR and HER2

exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018 Apr 23. doi: 10.1038/s41591-018-0007-9. [Epub ahead of print].

41. Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenzov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA: Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 March 20;36(9):841-849.
42. Ricciardi GR, Russo A, Franchina T, Ferraro G, Zanghì M, Picone A, Scimone A, Adamo V.: NSCLC and HER2: between lights and shadows. J Thorac Oncol. 2014 Dec;9(12):1750-62.
43. Rossi ED, Gerhard R, Cirnes L, Machado JC, Schmitt F.: Detection of common and less frequent EGFR mutations in cytological samples of lung cancer. Acta Cytol. 2014;58(3):275-80.
44. Sahoo R, Harini VV, Babu VC, Patil Okaly GV, Rao S, Nargund A, Venkataswamy E, Rao R, Kumar BS.: Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer. 2011 Sep;73(3):316-9.
45. Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Kawano O, Yukiue H, Yokoyama T, Yano M, Fujii Y.: EGFR exon 20 insertion mutation in Japanese lung cancer. Lung Cancer. 2007 Dec;58(3):324-8.
46. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol. 2008 May 20;26(15):2442-9.
47. Sheikine Y, Rangachari D, McDonald DC, Huberman MS, Folch ES, VanderLaan PA, Costa DB.: EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review. Clin Lung Cancer. 2016 Nov;17(6):483-492.
48. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, Fujisawa T, Feng Z, Roth JA, Herz J, Minna JD, Gazdar AF.: Clinical and biological features associated with epidermal growth factor

receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005 Mar 2;97(5):339-46.

49. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W.: Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W.: A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011 Jan;13(1):74-84.
50. Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors. Cold Spring Harb Symp Quant Biol. 2005;70:73-81.
51. Tsiambas E, Lefas AY, Georgiannos SN, Ragos V, Fotiades PP, Grapsa D, Stamatelopoulos A, Kavantzias N, Patsouris E, Syrigos K.: EGFR gene deregulation mechanisms in lung adenocarcinoma: A molecular review. Pathol Res Pract. 2016 Aug;212(8):672-7.
52. Tsigelny IF, Wheler JJ, Greenberg JP, Kouznetsova VL, Stewart DJ, Bazhenova L, Kurzrock R.: Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer. Oncotarget. 2015 Mar 20;6(8):6029-39.
53. Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL.: A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer. Lung Cancer. 2017 Dec;114:96-102.
54. Vlastos F, Zinzner J, Hussenet T, du Manoir S, Vordonis L, Nikolakopoulou S, Hardavella G, Lacomme S, Vignaud JM, Martinet N.: Mapping EGFR1 mutations in patients with lung adenocarcinoma. Diagn Mol Pathol. 2010 Dec;19(4):209-17
55. Voon PJ, Tsui DW, Rosenfeld N, Chin TM.: EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib--Letter. Mol Cancer Ther. 2013 Nov;12(11):2614-5.

56. Wheler JJ, Tsimberidou AM, Falchook GS, Zinner RG, Hong DS, Fok JY, Fu S, Piha-Paul SA, Naing A, Kurzrock R.: Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013 Oct;12(10):2167-75.
57. Willmore-Payne C, Holden JA, Layfield LJ.: Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. Hum Pathol. 2006 Jun;37(6):755-63.
58. Woo HS, Ahn HK, Lee HY, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK.: Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors. Invest New Drugs. 2014 Dec;32(6):1311-5.
59. Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY, Yang PC.: Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011 Jun 1;17(11):3812-21.
60. Wu TH, Hsiue EH, Lee JH, Lin CC, Yang JC.: m 2792706015. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Expert Rev Respir Med. 2017 Jan;11(1):51-55.
61. Xu W, Soga S, Beebe K, Lee MJ, Kim YS, Trepel J, Neckers L.: Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br J Cancer. 2007 Sep 17;97(6):741-4
62. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL.: Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul;16(7):830-8.
63. Yang M, Xu X, Cai J, Ning J, Wery JP, Li QX.: NSCLC harboring EGFR exon-20 insertions after the regulatory C-helix of kinase domain responds poorly to known EGFR inhibitors. Int J Cancer. 2016 Jul 1;139(1):171-6.

64. Yang WJ, Gao YB, Qiu T, Wang YG, He J.: Effectiveness of tyrosine kinase inhibitors against non-small cell lung cancer patients with postoperative recurrence harboring uncommon EGFR mutations. Zhonghua Zhong Liu Za Zhi. 2017 Oct 23;39(10):732-736.
65. Yasuda H, Kobayashi S, Costa DB.: EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 2012 Jan;13(1):e23-31.
66. Yasuda H, Park E, Yun CH, Sng NJ, Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S, Ishioka K, Yamaguchi N, Hanna M, Oxnard GR, Lathan CS, Moran T, Sequist LV, Chaft JE, Riely GJ, Arcila ME, Soo RA, Meyerson M, Eck MJ, Kobayashi SS, Costa DB.: Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18;5(216):216ra177.
67. Zhang J, Liang ZY, Zeng X, Wu SF, Gao J, Liu TH.: [Detection of epidermal growth factor receptor gene mutations in non-small cell lung cancers by real-time polymerase chain reaction using scorpion amplification refractory mutation system]. Zhonghua Bing Li Xue Za Zhi. 2008 May;37(5):294-9. Chinese.
68. Zhang Y, Wang Z, Hao X, Hu X, Wang H, Wang Y, Ying J.: Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations. Chin J Cancer Res. 2017 Feb;29(1):18-24.
69. Zhong WZ, Zhou Q, Wu YL.: The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer. Oncotarget. 2017 Aug 17;8(41):71358-71370.
70. Zou B, Lee VHF, Yan H.: Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis. BMC Bioinformatics. 2018 Mar 7;19(1):88.
71. Zupa A, Vita G, Landriscina M, Possidente L, Aieta M, Tartarone A, Improta G.: Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. Med Oncol. 2012 Dec;29(5):3198-201.

HER2/ERBB2 Receptor Exon 20 mutations

1. Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M.: Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin Cancer Res. 2012 Sep 15;18(18):4910-8.
2. Bu S, Wang R, Pan Y, Yu S, Shen X, Li Y, Sun Y, Chen H.: Clinicopathologic Characteristics of Patients with HER2 Insertions in Non-small Cell Lung Cancer. Ann Surg Oncol. 2017 Jan;24(1):291-297.
3. Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, Paolizzi D, Lattanzio G, Salvatore S, Campese PP, Rosini S, Iarussi T, Mucilli F, Sacco R, Mezzetti A, Marchetti A.: Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. Int J Cancer. 2006 Dec 1;119(11):2586-91.
4. Connell CM, Doherty GJ.: Activating HER2 mutations as emerging targets in multiple solid cancers. ESMO Open. 2017 Nov 24;2(5):e000279. doi: 10.1136/esmoopen-2017-000279. eCollection 2017. Review.
5. Costa DB, Jorge SE, Moran JP, Freed JA, Zerillo JA, Huberman MS, Kobayashi SS.: Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. J Thorac Oncol. 2016 Jun;11(6):918-23.
6. De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P, Schallier D.: Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer. 2012 Apr;76(1):123-7.
7. Eng J, Hsu M, Chaft JE, Kris MG, Arcila ME, Li BT.: Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers. Lung Cancer. 2016 Sep;99:53-6.
8. Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock R. Non-small-cell lung cancer with HER2 **exon 20** mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb;8(2):e19-20.
9. Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC.: Phase I Study of Neratinib in Combination With

Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors. Journal of Clinical Oncology 2014 32:2, 68-75

10. Hotta K, Aoe K, Kozuki T, Ohashi K, Ninomiya K, Ichihara E, Kubo T, Ninomiya T, Chikamori K, Harada D, Nogami N, Hirata T, Hinotsu S, Toyooka S, Kiura K. A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2018 Feb;13(2):273-279.
11. Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.: HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018 Feb 8;554(7691):189-194.
12. Jänne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, Millham R, Taylor I, Eckhardt SG, Schellens JH.: Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011 Mar 1;17(5):1131-9.
13. Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.: Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res. 2017 May 15;77(10):2712-2721.
14. Krawczyk P, Nicoœ M, Powrózek T, Mlak R, Sawicki M, Jarosz B, Pająk B, Kucharczyk K, Stencel D, Trojanowski T, Milanowski J.: Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system. Oncol Lett. 2013 Oct;6(4):1063-1067.
15. Kris MG, Camidge DR, Giaccone G, Hida T, Li BT, O'Connell J, Taylor I, Zhang H, Arcila ME, Goldberg Z, Jänne PA.: Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015 Jul;26(7):1421-7.

16. Kosaka T, Tanizaki J, Paranal RM, Endoh H, Lydon C, Capelletti M, Repellin CE, Choi J, Ogino A, Calles A, Ercan D, Redig AJ, Bahcall M, Oxnard GR, Eck MJ, Jänne PA.: Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res. 2017 May 15;77(10):2712-2721.
17. Li BT, Lee A, O'Toole S, Cooper W, Yu B, Chaft JE, Arcila ME, Kris MG, Pavlakis N. HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinib. Lung Cancer. 2015 Dec;90(3):617-9.
18. Li, BT, Ronglai, S, Buonocore, D, Olah, ZT, Ni, A, Ginsberg, MS, Ulaner, G, Weber, W, Ladyani, M, Won, HH, Riely, GJ, Solit, DB, Hyman, DM, Rudin, CM, Berger, MF, Scaltriti, M, Baselga, J, Kris, MG, Arcila, ME. Ado-trastuzumab emtansine in patients with HER2 mutant lung cancers: Results from a phase II basket trial. J Clin Oncol 35, 2017 (suppl; abstr 8510)
19. Li BT, Ross DS, Aisner DL, Chaft JE, Hsu M, Kako SL, Kris MG, Varella-Garcia M, Arcila ME. HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers. J Thorac Oncol. 2016 Mar;11(3):414-9.
20. Liu S, Li S, Hai J, Wang X, Chen T, Quinn MM, Gao P, Zhang Y, Ji H, Cross D, Wong KK.: Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. Clin Cancer Res. 2018 Jan 3. [Epub ahead of print]
21. Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O.: Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol. 2016 Feb;27(2):281-6.
22. Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Filip E, Rouquette I, Milia JD, Gautschi O.: Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol. 2013 Jun 1;31(16):1997-2003.
23. Nicoś M, Krawczyk P, Mlak R, Sawicki M, Jarosz B, Powrózek T, Milanowski P, Trojanowski T, Milanowski J.: The presence of HER2 exon 20 insertion in patients with central nervous system metastases from non-small lung cancer--a potential application in classification for therapy. Pneumonol Alergol Pol. 2013;81(4):294-7.

24. Ohashi K, Hotta K, Hirata T, Aoe K, Kozuki T, Ninomiya K, Kayatani H, Yanai H, Toyooka S, Hinotsu S, Takata M, Kiura K.: Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. Clin Lung Cancer. 2017 Jan;18(1):92-95.
25. Peters S, Zimmermann S.: Targeted therapy in NSCLC driven by HER2 insertions. Transl Lung Cancer Res. 2014 Apr;3(2):84-8.
26. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB^{6,7}, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med. 2018 Apr 23. doi: 10.1038/s41591-018-0007-9. [Epub ahead of print].
27. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H, Wistuba II, Fong KM, Toyooka S, Shimizu N, Fujisawa T, Minna JD, Gazdar AF.: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005 Mar 1;65(5):1642-6.
28. Sonobe M, Manabe T, Wada H, Tanaka F.: Lung adenocarcinoma harboring mutations in the ERBB2 kinase domain. J Mol Diagn. 2006 Jul;8(3):351-6.
29. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, Stevens C, O'Meara S, Smith R, Parker A, Barthorpe A, Blow M, Brackenbury L, Butler A, Clarke O, Cole J, Dicks E, Dike A, Drozd A, Edwards K, Forbes S, Foster R, Gray K, Greenman C, Halliday K, Hills K, Kosmidou V, Lugg R, Menzies A, Perry J, Petty R, Raine K, Ratford L, Shepherd R, Small A, Stephens Y, Tofts C, Varian J, West S, Widaa S, Yates A, Brasseur F, Cooper CS, Flanagan AM, Knowles M, Leung SY, Louis DN, Looijenga LH, Malkowicz B, Pierotti MA, Teh B, Chenevix-Trench G, Weber BL, Yuen ST, Harris G, Goldstraw P, Nicholson AG, Futreal PA, Wooster R, Stratton MR.: Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature. 2004 Sep 30;431(7008):525-6.
30. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W.: A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn. 2011 Jan;13(1):74-84.

31. Willmore-Payne C, Holden JA, Layfield LJ.: Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. Hum Pathol. 2006 Jun;37(6):755-63.
32. Xu W, Soga S, Beebe K, Lee MJ, Kim YS, Trepel J, Neckers L.: Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition. Br J Cancer. 2007 Sep 17;97(6):741-4.

Collected and Curated by:

Shelley B. Blam, PhD

Senior Advisor, Cancer Biology, ICAN Biomarkers Council

Principal Scientist, Cancer Biology Working Group, Exon 20 Group